CClinicalTrials.gg
CompletedNCT03954223TimeLEAdUpdated Mar 4, 2024Results posted

Time Limited Eating in Adolescents (Time LEAd): a Pilot Study

An interventional study of Low sugar and carbohydrate diet and Time Limited Eating in Obesity, Childhood, sponsored by Children's Hospital Los Angeles. Completed at 1 site in United States. Open to participants aged 14 Years to 18 Years. Per ClinicalTrials.gov, last updated 2024-03-04.

Sponsored by Children's Hospital Los Angeles · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
14 Years to 18 Years
Sex
All
01

Study summary

The investigators propose a randomized controlled trial in 90 children (age 13-21y) with obesity recruited from clinical programs at the Children's Hospital Los Angeles (CHLA). Patients will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback). Group 2) LSC+TLE (16-hour fast/8-hour feed for 3 days per week) + blinded CGM, Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).

Read the detailed description

The majority of adolescents with obesity demonstrate declining beta cell (β-cell) function and progressive insulin resistance over their lifetime.1 In our population of lower income minority teens, 1 in 3 have obesity or severe obesity and of those 30-50% go on to develop PD or T2D during adolescence or as young adults.1 Although diet and increased adiposity play a significant role in the pathogenesis of these conditions, the standard treatment model of intensive lifestyle modifications often result in modest decrease in BMI z-score of -0.1-0.2 SD.2, 3 There is a paucity of trials that have examined the effect of time limited eating (TLE) interventions in the treatment of youth with obesity.4 Novel dietary approaches like time limited eating have been shown to be effective for weight loss and improved glycemic control in adults with obesity but have not been examined in children.5, 6 A TLE approach involves interspersing normal daily caloric intake with 16-hour periods of calorie restriction/fasting several times a week.7-9 TLE may actually be more feasible, non-stigmatizing, flexible and effective for adolescents than alternatives like severe caloric restriction because it removes the need for intensive counting of daily caloric intake or macronutrient content and focuses on a straightforward task of consuming food during a pre-specified time period.4, 10, 11 One major limitation to implementing any dietary intervention in pediatric populations is concern for poor adherence and difficulty in reliably assessing compliance. We aim to overcome these issues with the use of continuous glucose monitoring (CGM) to monitor and promote adherence to the intervention and thus improve overall efficacy. In addition, the use of CGM will provide important outcome data related to overall glycemic response. Finally, we will evaluate whether providing individual feedback based on CGM data to subjects as real time biofeedback as part of the intervention, enhances efficacy. We propose a randomized controlled trial in 60 children (age 14-18) with obesity (BMI% > 95th percentile) recruited from clinical programs at the Children's Hospital Los Angeles (CHLA). Patients will be randomized to one of three treatment groups for a 12-week intervention: Group 1) Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback). Group 2) LSC+TLE (16-hour fast/8-hour feed for 5 days per week) + blinded CGM, Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).

We have 3 Specific Aims:

Aim 1. Test the efficacy of adding a TLE approach to a LSC intervention on body fat and weight loss (Group 2 vs. Group 1). Hypothesis 1: LSC+TLE will result in greater decrease in body fat and zBMI than LSC alone.

Aim 2. Test the efficacy of LSC+TLE compared to LSC alone on reduction on glycemic response (CGM) and psychosocial parameters (Group 2 vs. Group 1). Hypothesis 2: TLE+LSC will result in a greater improvement in glucose control (FBG) and psychosocial parameters.

Aim 3. Evaluate if CGM use is a feasible tool to determine dietary compliance to TLE type interventions and determine the impact of unblinded CGM on dietary intervention adherence and efficacy (Group 3 vs. Group 2). Hypothesis 3a: CGM will be a feasible tool to determine dietary compliance. Hypothesis 3b: Unblinded CGM data will result in 1) improved adherence to the dietary intervention as assessed by percent time in range when compared to those wearing a blinded CGM and 2) improve intervention effects.

Overall Impact: This research will generate new knowledge that can readily be integrated into clinical weight management programs to optimize their impact and accelerate healthy changes for youth with obesity. This dietary intervention could lead to global improvement and result in slowed disease progression, decreased complications and reduced prevalence of secondary comorbidities that arise from a lifetime of obesity.

Virtual Adaptation: To respond to the COVID-19 research restriction the study protocol was adapted for a 100% virtual model in which all study procedures, consent and outcome measures were collected virtually. For this cohort the aim was to recruit 10-12 completer per study arm with a maximum anticipated recruitment of 20-30 adolescents per group. For the virtual adaptation there is no DEXA scan or blood testing that is collected due to the in-person restriction.

02

Conditions studied

  • Obesity, Childhood

Browse trials for

03

In context

Pediatric Obesity

1,117 studies on the registry are indexed under Pediatric Obesity; 189 are open to participants now.

This study's enrollment of 50 is below the median of 103 across 862 interventional studies indexed under Pediatric Obesity.

Browse Pediatric Obesity studies →

Lead sponsor

Children's Hospital Los Angeles is the lead sponsor of 150 studies on the registry; 46 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. age 14-18
  2. BMI> 85th percentile
  3. parent, guardian or family member ages 18 years and older willing to participate

Exclusion criteria

Exclusion Criteria:

  • Insulin requirement

    1. previous diagnosis of Prader Willi Syndrome, brain tumor or hypothalamic obesity
    2. serious mental conditions (e.g. developmental or intellectual disability or previously diagnosed eating disorder or positive screen at consent visit)
    3. physical, mental of other inability to participate in the assessments (e.g. inability to wear CGM, inability to be in the imaging modality without sedation, or inability to eat by mouth)
    4. previous or planned bariatric surgery
    5. current use of medication that impacts weight or executive functioning (e.g., antipsychotics, sedatives, hypnotics, off-label obesity medication)
    6. current psychotherapy regarding weight or eating behavior
    7. current participation in other interventional studies. In our experience, children younger than 13 years of age and older than 21 years would require different intervention/counseling strategies.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    LSC + blinded CGM

    Group 1) Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day) + blinded CGM (used to monitor adherence and glycemic outcomes without real time feedback)

    Behavioral: Low sugar and carbohydrate diet · Device: Continuous Glucose Monitor

  • Experimental
    LSC+TLE + blinded CGM

    Group 2) LSC+Time limited eating (TLE) (16-hour fast/8-hour feed for 3 days per week) + blinded CGM

    Behavioral: Low sugar and carbohydrate diet · Behavioral: Time Limited Eating · Device: Continuous Glucose Monitor

  • Experimental
    LSC+TLE+ real time feedback via CGM

    Group 3) LSC+TLE+ real time feedback via CGM (to evaluate effect of providing CGM data on intervention efficacy).

    Behavioral: Low sugar and carbohydrate diet · Behavioral: Time Limited Eating · Device: Continuous Glucose Monitor

Interventions

  • BehavioralLow sugar and carbohydrate diet

    Low sugar and carbohydrate diet (LSC, \<90 gm carbohydrate (CHO)/day, \<25 gm added sugar/day)

    Also known as: LSC

  • BehavioralTime Limited Eating

    16-hour fast/8-hour feed for 3 days per week

    Also known as: TLE

  • DeviceContinuous Glucose Monitor

    CGM (used to monitor adherence and glycemic outcomes without real time feedback)

    Also known as: CGM

06

What researchers measure

Primary outcomes

  1. Percent Change in BMI in Excess of the 95th Percentile (%BMIp95)

    Percent Change in BMI in excess of the 95th percentile (%BMIp95) as calculated by the CDC extended SAS equations at week 12 minus %BMIp95 at baseline. For example If the BMI is greater than the 95th percentile: BMI percentile equals 90 plus 10 times the cumulative distribution function (CDF) of the standard normal distribution. Sigma is the value from the data table corresponding to the sex of the child and the age in months. and are the cumulative distribution function (CDF) of the standard normal distribution and its inverse function. Standard normal distribution tables can be found in statistics textbooks, online sources, and statistical computer programs. Example: A boy aged 4 years and 2 months (50.5 months) with BMI = 22.6. For this boy, P95 (95th percentile) is 17.8219 so his BMI is above the 95th percentile and sigma = 2.3983.

    Time frame: %BMIp95 at Week 12 minus %BMIp95 at baseline

Secondary outcomes

  1. Average Glucose

    Affect of TRE on change in average glucose

    Time frame: Change in average glucose at week 12 minus average glucose at baseline

07

Results

Posted Apr 6, 2023

Participant flow

Participant flow — Overall Study
MilestoneLSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGM
Started151916
Completed151916
Not completed000

Outcome measures

PrimaryPercent Change in BMI in Excess of the 95th Percentile (%BMIp95)

Percent Change in BMI in excess of the 95th percentile (%BMIp95) as calculated by the CDC extended SAS equations at week 12 minus %BMIp95 at baseline. For example If the BMI is greater than the 95th percentile: BMI percentile equals 90 plus 10 times the cumulative distribution function (CDF) of the standard normal distribution. Sigma is the value from the data table corresponding to the sex of the child and the age in months. and are the cumulative distribution function (CDF) of the standard normal distribution and its inverse function. Standard normal distribution tables can be found in statistics textbooks, online sources, and statistical computer programs. Example: A boy aged 4 years and 2 months (50.5 months) with BMI = 22.6. For this boy, P95 (95th percentile) is 17.8219 so his BMI is above the 95th percentile and sigma = 2.3983.

Time frame:
%BMIp95 at Week 12 minus %BMIp95 at baseline
Reported as:
Mean · percent
Percent Change in BMI in Excess of the 95th Percentile (%BMIp95)
percentLSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGM
Percent Change in BMI in Excess of the 95th Percentile (%BMIp95)-3.27 ± 3.34-3.76 ± 5.76-4.85 ± 5.08
Statistical analysis
  • LSC + Blinded CGM vs LSC+TLE + Blinded CGM vs LSC+TLE+ Real Time Feedback Via CGM · ANOVA · p = 0.4
SecondaryAverage Glucose

Affect of TRE on change in average glucose

Time frame:
Change in average glucose at week 12 minus average glucose at baseline
Reported as:
Mean · mg/dL
Average Glucose
mg/dLLSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGM
Average Glucose0.5 (-20.2 to 6.0)-7.1 (-18.2 to 6.0)-4.2 (-14.7 to 6.1)
Statistical analysis
  • LSC + Blinded CGM vs LSC+TLE + Blinded CGM vs LSC+TLE+ Real Time Feedback Via CGM · Regression, Linear · p = 0.2 · Median difference (final values): -7.0Mixed-effects generalized linear model of the glycemic profile change extracted from CGM data.

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LSC + Blinded CGM0/15 (0%)0/15 (0%)0/15 (0%)
LSC+TLE + Blinded CGM0/19 (0%)0/19 (0%)0/19 (0%)
LSC+TLE+ Real Time Feedback Via CGM0/16 (0%)0/16 (0%)0/16 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)LSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGMTotal
<=18 years15191650
Between 18 and 65 years0000
>=65 years0000
Age, Continuous
Age, Continuous(year)LSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGMTotal
Mean16.38 ± 1.2516.16 ± 1.1616.80 ± 1.0916.80 ± 1.09
Sex: Female, Male
Sex: Female, Male(Participants)LSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGMTotal
Female12131136
Male36514
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGMTotal
Hispanic or Latino7151335
Not Hispanic or Latino84315
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)LSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGMTotal
United States15191650
BMI Z-score
BMI Z-score(Z-score)LSC + Blinded CGMLSC+TLE + Blinded CGMLSC+TLE+ Real Time Feedback Via CGMTotal
Mean2.30 ± 0.52.28 ± 0.42.30 ± 0.52.30 ± 0.5
08

Study locations

1 site
  • Children's Hospital of Los Angeles
    Los Angeles, California 90027, United States
09

References and documents

Publications

  • Naguib MN, Hegedus E, Raymond JK, Goran MI, Salvy SJ, Wee CP, Durazo-Arvizu R, Moss L, Vidmar AP. Continuous Glucose Monitoring in Adolescents With Obesity: Monitoring of Glucose Profiles, Glycemic Excursions, and Adherence to Time Restricted Eating Programs. Front Endocrinol (Lausanne). 2022 Feb 25;13:841838. doi: 10.3389/fendo.2022.841838. eCollection 2022. PubMed 35282464 ↗
  • Vidmar AP, Goran MI, Naguib M, Fink C, Wee CP, Hegedus E, Lopez K, Gonzalez J, Raymond JK. Time limited eating in adolescents with obesity (time LEAd): Study protocol. Contemp Clin Trials. 2020 Aug;95:106082. doi: 10.1016/j.cct.2020.106082. Epub 2020 Jul 16. PubMed 32682994 ↗

Study documents

  • Protocol, analysis plan and consent form · Feb 6, 2023

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

10

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 4, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03954223
Lead sponsor
Children's Hospital Los Angeles
Responsible party
Alaina P. Vidmar, MD (Assistant Professor of Clinical Pediartrics, Children's Hospital Los Angeles) — Principal investigator
First posted
May 17, 2019
Start date
Mar 1, 2020
Primary completion
Jan 30, 2022
Completion
Mar 1, 2022
Results posted
Apr 6, 2023
Last update
Mar 4, 2024

Study contacts

Alaina Vidmar, MD
principal investigator · Children's Hospital Los Angeles

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion